NewLink's IMPRESS results disappoint

May 10, 2016 News BioVox

NewLink Genetics Corp. (NASDAQ:NLNK) sank $5.50 (33%) to $11 in early after-hours trading Monday after it said HyperAcute Pancreas algenpantucel-L missed the primary overall survival endpoint in the Phase III IMPRESS study to treat resected pancreatic cancer. Median survival among patients treated with algenpantucel-L plus standard of care (SOC) was 27.3 months vs. 30.4 months for SOC alone in the 722-patient study.

Algenpantucel-L is an allogeneic cancer vaccine containing irradiated pancreatic tumor cells modified to express 1,3-galactosyltransferase.

The company now plans to focus its efforts elsewhere in its pipeline, which includes indoleamine 2,3-dioxygenase (INDO; IDO) inhibitors indoximod (NLG8189) and GDC-0919. The company anticipates interim data next month from a Phase II study of indoximod to treat metastatic pancreatic cancer. It expects its partner, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), to report data in October from a Phase Ib study of GDC-0919 plus atezolizumab (MPDL3280A) to treat solid tumors.

Full article at BioCentury

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts


* indicates required

Intuit Mailchimp